AMVUTTRA™ safety and tolerability profile
Adverse Reaction |
AMVUTTRA N=122 (%) |
---|---|
Arthralgiaa | 11 |
Dyspneaa | 7 |
Vitamin A Decreasedb | 7 |
aComprised of several similar terms.
bPercentage only reflects those reported as an adverse reaction.
aExternal placebo group from APOLLO. Mean duration of exposure was 15 months (range: 1.3-18.8 months).
bIncludes dyspnea, dyspnea exertional, and dyspnea paroxysmal nocturnal.
Adverse Reaction |
AMVUTTRA N=122 (%) |
---|---|
Arthralgiaa | 11 |
Dyspneaa | 7 |
Vitamin A Decreasedb | 7 |
aComprised of several similar terms.
bPercentage only reflects those reported as an adverse reaction.
- The safety profile of AMVUTTRA was generally consistent across all subgroups2,c
- There were no drug-related discontinuations or deaths in patients treated with AMVUTTRA3
- Injection site reactions occurred in 4% of patients and were mild and transient1,4
- There are no contraindications for AMVUTTRA1
- After 18 months of treatment, the most common adverse events reported in patients treated with AMVUTTRA were pain in extremity, arthralgia, abdominal pain, vitamin A decreased, dyspnea, and troponin T increased2
cSubgroups included age, sex, V30M variant status, previous TTR stabilizer use, and disease stage.2